CELSION to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference.

COLUMBIA, Md. -- CELSION CORPORATION (AMEX: CLN), a drug development company that is leveraging its technology platform to encapsulate and deliver a higher concentration of proven cancer killing drugs. today announced that Michael H. Tardugno, president and chief executive officer, will deliver a corporate presentation at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference. The conference will be held November 5-7, 2007, at the New York Palace Hotel in New York City.

The presentation will take place on Monday, November 5th in the Kennedy I room at 4:25 PM and will immediately be followed by a Q&A session. Mr. Tardugno will provide an update on the company's activities, including execution of the company's strategy to achieve two critical goals: the clinical success and regulatory approval of our initial cancer fighting drug, Thermodox([R]), and, at the same time, the identification, development and growth of a solid pipeline of additional chemotherapeutics having the potential for treatment of additional indications.

A 90-day archive of the presentation can be accessed at http://www.celsion.com.

About Thermodox

ThermoDox is Celsion's proprietary heat-sensitive liposomal encapsulation of an approved and frequently used anti-cancer drug, doxorubicin which is used in the treatment of various cancers including breast cancer. Localized mild hyperthermia (39-42 degrees C) releases the entrapped doxorubicin from the liposome. This delivery technology enables high concentrations of doxorubicin to be deposited preferentially in a targeted tumor.

About Celsion:

Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, North Shore Long Island Jewish Health System. Additional information about Celsion Corporation can be found on the Celsion web site at www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.